^
Association details:
| Biomarker: | EGFR mutation + CDCA3 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1013P - Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer
Published date:
09/05/2022
Excerpt:
A tissue-microarray of 150 tumors and panel of 13 NSCLC adenocarcinoma cell line panel were screened….Consistently, low CDCA3 expression (H-score < median) correlated with emergence of TKI resistance (p < 0.01) and in a panel of EGFRmut cell lines, CDCA3 low cell lines demonstrated significantly reduced potency for erlotinib and Osimertinib (p = 0.018).
